FDA advisory panel unanimously backs biosimilars for Humira, Enbrel

The Food and Drug Administration’s Arthritis Advisory Committee, together with an added complement of dermatologists and gastroenterologists, unanimously recommended during meetings on July 12 and 13 that the agency license a biosimilar Humira (adalimumab) that is made by Amgen and a biosimilar...
Source: Skin and Allergy News - Category: Dermatology Source Type: news